NCT00268619已完成3 期
A Placebo-controlled, Double-blind, Randomized, Multicenter Study of Ramipril 5 and 10 mg Capsules and Insulin Infusion in Subjects With Unstable Coronary Syndromes
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Sanofi
- 主要终点
- To assess the highly specific C-reactive protein (hsCRP) blood levels
研究概览
简要总结
Study objectives:
- To demonstrate that the acute administration of ramipril will control the inflammation process in patients with high-risk Acute Coronary Syndrome (ACS) as assessed by the high sensitivity C-reactive protein blood levels.
- To demonstrate that the normalization of blood glucose levels with intravenous insulin will improve the inflammation process during the acute phase of an ACS as assessed by Tumor necrosis factor alpha blood levels.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject either not of childbearing potential or is not pregnant and agrees to use contraceptive measure for the duration of the study
- •Subjects presenting within 12 hours after the last episode of chest pain with:
- •An accelerating pattern of anginal pain
- •A prolonged or recurrent anginal pain at rest or with minimal effort AND
- •Evidence of myocardial ischemia on ECG manifested by at least one of the following ECG criteria: - new persistent or transient ST-segment depression OR transient or reversible ST-segment elevation or new persistent or transient T-wave inversion OR Abnormal cardiac markers defined as: CK-MB greater than the upper limit of normal Troponin T or I level greater than the upper limit of normal.
排除标准
- •Known or suspected pregnancy or actively breast-feeding
- •Female of childbearing potential not using or planning to use a reliable method of contraception
- •Treatment with Hormone Replacement Therapy at time of randomization
- •Angina precipitated by obvious provoking factors
- •Heart Failure defined as known ejection fraction less or equal to 40% or NYHA (New York Heart Association) class III pr IV
- •Type I Diabetes Mellitus
- •Type II diabetes requiring insulin therapy
- •Hyperkaliemia
- •Acute chronic inflammatory, collagen tissue disease, auto-immune disease or cancer and/or requiring the use of anti-inflammatory or anti-neoplastic agents at the time of randomization
- •Use of a non-steriodal anti-inflammatory agent, coxibs, or anti-neoplasic agent within last 7 days
- •Use of any oral or intra-venous steroidal agent in the last 7 days before study entry
- •Uncontrolled hypertension
- •Systolic pressure < 100 mmHg at randomization
- •Likelihood of requiring treatment during the study period with drugs not permitted by the protocol
- •Treatment with any investigational product or device in the last 4 weeks
- •Previous participation into the trial
- •History of hypersensitivity, allergy, or intolerance to Angiotensin-Converting Enzyme inhibitors.
- •Severe cardiovascular diseases requiring urgent therapy
- •Severe or co-morbid condition
- •History of cancer not known to be disease free, with the exception of basal cell carcinoma of the skin
- •Clinically important systemic disorder
- •Impaired hepatic function
- •Clinically important chronic or acute renal failure
- •History of drug or alcohol abuse
结局指标
主要结局
To assess the highly specific C-reactive protein (hsCRP) blood levels
时间窗: during the study conduct
To assess the tumor necrosing factor alpha (TNFα) blood levels
时间窗: during the study conduct
次要结局
- TEAEs collection(From the signature of the informed consent up to the end of the study)
研究者
相似试验
终止
3 期
A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and AdolescentsHypertensionNCT00389519Pfizer422
终止
3 期
Study of Rifampicin in Multiple System AtrophyMultiple System AtrophyNCT01287221Phillip Low100
已完成
4 期
Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To SirolimusKidney TransplantNCT00502242Pfizer229
Unknown
3 期
The Effect of Ramipril in Suppressing ST2 Expression in Rheumatic Mitral Stenosis PatientsRheumatic Mitral StenosisACE InhibitorRheumatic Heart DiseaseHeart FibrosisMitral StenosisNCT03991910Indonesia University66
已完成
3 期
Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)Irritable Bowel Syndrome With DiarrheaNCT00552565AGI Therapeutics, Inc.711